Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.
Schizophr Res
; 79(2-3): 281-8, 2005 Nov 15.
Article
en En
| MEDLINE
| ID: mdl-15964743
ABSTRACT
There is a growing concern regarding the propensity of second generation antipsychotics (SGAs) to induce weight gain and metabolic adverse effects. Recent consensus guidelines have recommended assessment and monitoring procedures to appropriately detect and manage these adverse effects. This study addresses the appreciation and readiness of clinicians to implement management guidelines for these adverse effects. Respondents indicated awareness of the risks of treatment with SGAs. The extent of monitoring for metabolic adverse effects was low and inconsistent across measures and in frequency of evaluation. Ongoing efforts are needed to support and encourage change in clinician practice.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Esquizofrenia
/
Antipsicóticos
/
Aumento de Peso
/
Reconocimiento en Psicología
/
Enfermedades Metabólicas
Tipo de estudio:
Guideline
/
Qualitative_research
Límite:
Humans
Idioma:
En
Revista:
Schizophr Res
Asunto de la revista:
PSIQUIATRIA
Año:
2005
Tipo del documento:
Article
País de afiliación:
Estados Unidos